Abstract:Abstract Solid tumor tumors contain hypoxic regions. Tumor hypoxia is co-present with reduced nutrients and usually intracellular acidification. Lack of O2 and nutrients, and intracellular acidification causes endoplasmic reticulum stress (ER). In addition to canonical hypoxia response, tumor cells activate integrated ER-stress response (IERSR) in a spatially and temporally regulated manner to enter into dormancy under hypoxia and de-activate IERSR to return to a proliferative state once blood supply is restored. Phosphorylation of the alpha subunit of eukaryotic translation initiation factor 2 (eIF2α) branch of IERSR is a critical determinant of tumor survival under hypoxia. Temporally and spatially regulated eIF2α phosphorylation attenuates overall translation while favoring translation of a subset of mRNAs coding for transcription factors and accessory proteins. This results in re-programming of gene expression that favors tumor-cell survival. Once the hypoxic conditions are ameliorated eIF2α phosphorylation is reversed and tumor cells exit dormancy. Sustained eIF2α phosphorylation on the other hand not only reduces overall protein synthesis to inhibit proliferation but also re-programs gene expression to induce expression of pro-apoptotic proteins such as CHOP to induce cell death. We therefore hypothesized that pharmacological activation of eIF2α kinases to induce sustained eIF2a phosphorylation will cause selective demise of tumors. To test this hypothesis and develop mechanism specific anti-cancer agents we generated high throughput reporter assays and screened large chemical libraries for inducers of eIF2α phosphorylation. Our Screening effort combined with functional genetic studies, and synthesis and evaluation of focused libraries resulted in identification of highly potent and specific activators of three eIF2α kinases, heme-regulated inhibitor (HRI), Protein kinase R, and PKR-like ER-kinase (PERK). These agents downregulate expression of pro-proliferative proteins such as cyclin D1 and cyclin E while upregulating the expression of pro-apoptotic proteins such as CHOP and tumor suppressor proteins such as BRCA1; all dependent on eIF2α phosphorylation. We will present unpublished data on the structure activity relationship studies of the second generation activators of eIF2α kinases. We will also present in vivo data demonstrating that inducers of eIF2α phosphorylation fully abrogate proliferation of human breast and melanoma xenografts growth with no apparent toxicity. At the molecular level, they induce eIF2α phosphorylation, expression of pro-apoptotic protein CHOP and cell cycle inhibitor p27Kip1 while inhibiting Cyclin D1 expression in xenograft tumors. Tumor cells acquire resistance to targeted therapy by bypassing the signaling node inhibited by treatment; activating alternate oncogenic pathway or downstream signaling node. Because translation initiation is in the apex of many oncogenic and proliferative pathways we hypothesized that translation initiation inhibitors will abrogate proliferation of targeted-therapy resistant cancer cell lines independent of the primary therapy or the mechanism of resistance. Our studies in melanoma cancer cells resistant to B-Raf or B-Raf and MEK inhibitors demonstrate that activators of eIF2α kinases or inhibitors of eIF4F complex inhibit the proliferation of parental and drug resistant cancer-cells with the same efficiency. We will also present these data and on our progress in resolving the crystal structure of full-length HRI which should allow us to accelerate drug development by improving the specificity and potency of our current lead compounds. We conclude that our second generation activators of eIF2α kinases are potent and mechanism specific agents that can be developed for treatment of naïve and drug resistant tumors. This abstract is also being presented as Poster B20. Citation Format: Revital Yefidoff-Freedman, Ronghui Du, Fan Jing, Quingwen Zhang, Bertal H. Aktas. Targeting eIF2α phosphorylation for cancer therapy. [abstract]. In: Proceedings of the AACR Special Conference on Translational Control of Cancer: A New Frontier in Cancer Biology and Therapy; 2016 Oct 27-30; San Francisco, CA. Philadelphia (PA): AACR; Cancer Res 2017;77(6 Suppl):Abstract nr PR12.

Abstract 1841: Investigating mechanisms of tumor eradication by blocking SIAH E3 ligase, a major tumor vulnerability, in EGFR/RAS-driven human cancer

Abstract P4-08-13: The Use of Reverse Phase Protein Arrays (RPPA), Principal Component Analysis (PCA), and CScape Pathway Mapping to Identify New Tumor Vulnerability and Actionable Targets in Human Malignant Triple-Negative Breast cancer cell lines

Abstract IA010: Engineering human sialidase as novel cancer therapeutics by targeting sialoglycans

Abstract PR12: Targeting Eif2α Phosphorylation for Cancer Therapy

Abstract 5499: Synergistic Effects of the Combination of ERK1/2 with EGFR, KRASG12C, CDK4/6, and PD-L1 Inhibition for Cancer Treatment

Abstract 3324: Discovery of a novel SOS1 inhibitor, AIG01012, targeting pan-KRAS mutant cancers

Abstract 3391: Dual inhibition of RAS and the IGF2/IGF1R pathways: a potential targeting strategy for RAS-mutated embryonal rhabdomyosarcoma

Abstract 3395: Polyisoprenylated cysteinyl amide inhibitors: Effects on RAS signaling pathway intermediates and viability of mutant KRAS African American lung cancer cell line

Abstract 5739: Targeting WEE1 to improve the therapy of KRAS G12C mutant non-small cell lung cancer

Abstract 3940: Small Molecule Profiling Uncovers the Landscape Uncovers the Landscape of Combinational PI3K Inhibitor Responses in HNSCC

Abstract 30: Small Molecule Profiling Uncovers the Landscape of Combinatorial PI3K Inhibitor Responses in HNSCC

Abstract A010: Using oncogenic pathway agonism to sensitize RAS-mutant cancers to immunotherapy

Abstract 1969: Off-target autophagy inhibition by SHP2 allosteric inhibitors and therapeutic implications for aberrant RAS-driven cancers

Abstract 3716: Enhancing anti-tumor responses in triple-negative breast cancer by combining SIRPα inhibition with immunogenic chemotherapy or antibody-drug conjugates

Abstract 3685: Targeting a novel cell surface serine protease TMPRSS11B for lung cancer therapy

Abstract A020: CETSA profiling unveils novel targets engaged by anti-tumor drug rigosertib to inhibit RAS-MAPK signaling and trigger NLRP3 inflammasome activation

Abstract 6506: SOS1 inhibition in combination with HER2 inhibition in models of HER2-driven cancer

Abstract 3313: Discovery of a potent, selective, and orally available small molecule for disruption of the SOS1-RAS interaction

Abstract B007: Proximal RTK signaling regulates tumor initiating cell survival and therapeutic responsiveness in EGFR- and KRAS-mutated lung adenocarcinoma

Abstract 1214: Investigating therapeutic strategies to promote immune rejection of KRASG12C inhibitor-resistant subpopulations in lung cancer

Abstract 4717: Small molecule modulation of PP2A selectively induces oncogenic cytotoxicity through chronic and irreversible integrated stress response